Post by Tony Crispino on Feb 10, 2014 14:50:31 GMT -8
I saw this in Medpage and later that day posted on HealingWell.
No Survival Benefit in CRPC With New Anti-Androgen
One key point was "Patients who received orteronel plus prednisone had a median overall survival (OS) of 17 months versus 15.2 months for patients treated with prednisone alone. Orteronel did lead to significantly better progression-free survival (PFS), a secondary endpoint of the trial."
The overall survival was deemed insignificant.
In our SWOG meeting today I raised the point of this article and there was a pretty big variation by region that basically killed this trial. Many patients in Europe were given Abiraterone prior to being accrued for the TAK-700 (orteronel) trial. The problem here is that both drugs use a similar mechanism, they are liase 17,20 inhibitors. So if the patient had failed abiraterone, then ortonel was not likely to help and the trial proved that. But because many patients who had failed abiraterone were accrued, there is no way to continue this trial and deliver the true effects of TAK700.
S1216, a current SWOG trial, is testing men prior to the use of abiraterone. Which makes sense. Moving forward, S1216 is still a valid and viable trial option for men with metastatic disease.
Tony
No Survival Benefit in CRPC With New Anti-Androgen
One key point was "Patients who received orteronel plus prednisone had a median overall survival (OS) of 17 months versus 15.2 months for patients treated with prednisone alone. Orteronel did lead to significantly better progression-free survival (PFS), a secondary endpoint of the trial."
The overall survival was deemed insignificant.
In our SWOG meeting today I raised the point of this article and there was a pretty big variation by region that basically killed this trial. Many patients in Europe were given Abiraterone prior to being accrued for the TAK-700 (orteronel) trial. The problem here is that both drugs use a similar mechanism, they are liase 17,20 inhibitors. So if the patient had failed abiraterone, then ortonel was not likely to help and the trial proved that. But because many patients who had failed abiraterone were accrued, there is no way to continue this trial and deliver the true effects of TAK700.
S1216, a current SWOG trial, is testing men prior to the use of abiraterone. Which makes sense. Moving forward, S1216 is still a valid and viable trial option for men with metastatic disease.
Tony
